115 related articles for article (PubMed ID: 16284192)
1. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Szapary PO; Bloedon LT; Samaha FF; Duffy D; Wolfe ML; Soffer D; Reilly MP; Chittams J; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):182-8. PubMed ID: 16284192
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Winkler K; Konrad T; Füllert S; Friedrich I; Destani R; Baumstark MW; Krebs K; Wieland H; März W
Diabetes Care; 2003 Sep; 26(9):2588-94. PubMed ID: 12941723
[TBL] [Abstract][Full Text] [Related]
6. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Olson EJ; Pearce GL; Jones NP; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
[TBL] [Abstract][Full Text] [Related]
7. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
[TBL] [Abstract][Full Text] [Related]
9. Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high-density lipoprotein cholesterol and features of metabolic syndrome.
Söderlund S; Watanabe H; Ehnholm C; Jauhiainen M; Taskinen MR
Metabolism; 2010 Oct; 59(10):1502-9. PubMed ID: 20206948
[TBL] [Abstract][Full Text] [Related]
10. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
11. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
Gupta M; Szmitko PE; Tsigoulis M; Braga MF; Kajil M; Herjikaka S; Quan A; Teoh H; Verma S
J Cardiovasc Pharmacol; 2010 Sep; 56(3):241-5. PubMed ID: 20505518
[TBL] [Abstract][Full Text] [Related]
12. Decreased high-density lipoprotein cholesterol is associated with inflammation and insulin resistance in non-diabetic haemodialysis patients.
Peng YS; Chiu YL; Chen HY; Yang JY; Lai CF; Hsu SP; Pai MF
Nephrology (Carlton); 2010 Oct; 15(7):692-9. PubMed ID: 21040164
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
[TBL] [Abstract][Full Text] [Related]
14. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Deeg MA; Buse JB; Goldberg RB; Kendall DM; Zagar AJ; Jacober SJ; Khan MA; Perez AT; Tan MH;
Diabetes Care; 2007 Oct; 30(10):2458-64. PubMed ID: 17595355
[TBL] [Abstract][Full Text] [Related]
16. Cholesteryl ester transfer protein in metabolic syndrome.
Sandhofer A; Kaser S; Ritsch A; Laimer M; Engl J; Paulweber B; Patsch JR; Ebenbichler CF
Obesity (Silver Spring); 2006 May; 14(5):812-8. PubMed ID: 16855190
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
18. Genistein in the metabolic syndrome: results of a randomized clinical trial.
Squadrito F; Marini H; Bitto A; Altavilla D; Polito F; Adamo EB; D'Anna R; Arcoraci V; Burnett BP; Minutoli L; Di Benedetto A; Di Vieste G; Cucinotta D; de Gregorio C; Russo S; Corrado F; Saitta A; Irace C; Corrao S; Licata G
J Clin Endocrinol Metab; 2013 Aug; 98(8):3366-74. PubMed ID: 23824420
[TBL] [Abstract][Full Text] [Related]
19. Hypoadiponectinemia: a useful marker of dyslipidemia in women with polycystic ovary syndrome.
Chang CY; Chen MJ; Yang WS; Yeh CY; Ho HN; Chen SU; Yang YS
Taiwan J Obstet Gynecol; 2012 Dec; 51(4):583-90. PubMed ID: 23276562
[TBL] [Abstract][Full Text] [Related]
20. The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Hanefeld M
Diabetes Obes Metab; 2009 Aug; 11(8):742-56. PubMed ID: 19519869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
